{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:33:06Z","timestamp":1777660386667,"version":"3.51.4"},"reference-count":34,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Genetic Testing and Molecular Biomarkers"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Recent discoveries indicate that the enzyme fatty acid 2-hydroxylase (FA2H) is associated with biological behavior and can be used for outcome prediction in several types of cancers. Such relevancy, however, between FA2H and ovarian cancer is not clear. Therefore, we carried out this study to compare the expression of FA2H with the clinicopathological features of ovarian cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Using the Oncomine database, we examined the expression levels of the\n                      <jats:italic toggle=\"yes\">FA2H<\/jats:italic>\n                      gene in ovarian cancer tissues and their adjacent noncancerous tissues that had been evaluated by quantitative reverse-transcription polymerase chain reaction (PCR) analyses. We performed Kaplan-Meier curve analyses for overall survival and progression-free survival. In addition, relationships between the FA2H expression levels and clinicopathological features of ovarian cancer were analyzed. Finally, FA2H small interfering RNAs (siRNAs) or negative control siRNAs were separately transfected into OVCAR-3 and SKOV-3 cells to explore the downstream effects. From these results,\n                      <jats:italic toggle=\"yes\">Gli1<\/jats:italic>\n                      expression was tested by real-time PCR, and the effects of FA2H expression levels on the sensitivity of ovarian cancer cells to cisplatin chemotherapy was evaluated using sulforhodamine B assays.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Compared with the adjacent tissues, FA2H was expressed at lower levels in the ovarian cancer tissues. In survival analyses, decreased FA2H was significantly associated with poorer survival outcome in multiple subtypes of ovarian cancer. In addition, FA2H expression was significantly associated with F\u00e9d\u00e9ration Internationale de Gyn\u00e9cologie et d'Obst\u00e9trique (FIGO) stage, differentiation, lymph node involvement, tumor size, ascites, CA125 levels, and pelvic involvement. Knockdown of FA2H expression by siRNAs in the OVCAR-3 and SKOV-3 cell lines reduced their sensitivity to cisplatin, via modulation of GLI Family Zinc Finger 1 (\n                      <jats:italic toggle=\"yes\">Gli1<\/jats:italic>\n                      ) gene expression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our results demonstrate that FA2H is a biomarker for ovarian cancer and it may serve as a useful prognostic factor.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/gtmb.2019.0259","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T11:18:22Z","timestamp":1602847102000},"page":"632-640","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Overexpression of Fatty Acid 2-Hydroxylase is Associated with an Increased Sensitivity to Cisplatin by Ovarian Cancer and Better Prognoses"],"prefix":"10.1177","volume":"24","author":[{"given":"Ting","family":"Qi","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynaecology, The First People's Hospital of Lianyungang, Lianyungang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dandan","family":"Wu","sequence":"additional","affiliation":[{"name":"International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhipei","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Oncology, Suzhou Ninth People's Hospital, Suzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Suzhou Ninth People's Hospital, Suzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajun","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Nantong Tongzhou People's Hospital, Nantong, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China."},{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M406649200"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.3892\/or.2014.3257"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/10.7.757"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2015.49"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature01972"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2981"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3483"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060145"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2006.11.033"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2017.03.004"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01089"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106913"},{"key":"e_1_3_3_14_1","first-page":"937","article-title":"Diagnosis and management of ovarian cancer","volume":"93","author":"Doubeni CA","year":"2016","unstructured":"Doubeni CA, , Doubeni AR, , Myers AE (2016) Diagnosis and management of ovarian cancer. Am Fam Physician, 93:937-944.","journal-title":"Am Fam Physician"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20041451"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2008.10.010"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2007.03.017"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81683-9"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-1981"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.2174\/156652409789105570"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbior.2013.09.012"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2011.610"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.6.20.4808"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M093955"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2222"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2018.06.036"},{"key":"e_1_3_3_28_1","first-page":"166","article-title":"Morphologic, immunophenotypic, and molecular features of epithelial ovarian cancer","volume":"30","author":"Ramalingam P","year":"2016","unstructured":"Ramalingam P (2016) Morphologic, immunophenotypic, and molecular features of epithelial ovarian cancer. Oncology (Williston Park), 30:166-176.","journal-title":"Oncology (Williston Park)"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.2174\/1871520618666181015142810"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21551"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.17305\/bjbms.2018.2756"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-4816-9"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-009-0617-5"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.01.066"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2009.01204.x"}],"container-title":["Genetic Testing and Molecular Biomarkers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/gtmb.2019.0259","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/gtmb.2019.0259","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/gtmb.2019.0259","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:22:21Z","timestamp":1777447341000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/gtmb.2019.0259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1089\/gtmb.2019.0259"],"URL":"https:\/\/doi.org\/10.1089\/gtmb.2019.0259","relation":{},"ISSN":["1945-0265","1945-0257"],"issn-type":[{"value":"1945-0265","type":"print"},{"value":"1945-0257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}